Crowdonomics
All companies
TRIAGENICS logo

TRIAGENICS

Operating

TriAgenics, Inc.

Healthcare · Redmond, OR · Founded 2013

Eliminating wisdom teeth extractions with a non-surgical procedure

Post-money valuation
$38.9M
As of Nov 2024 · from TriAgenics Preferred Stock 1 · pre-money + amount raised, not a traded price
Total raised
$4,913,921
Across 2 rounds since 2023
Latest share price
$4.50
Reg CF Offering (2025) offering price

Financials

FY2021–FY2025 · from SEC filings · hover any figure for its source
$0
−$1.1M
2021
$0
−$1.4M
2022
$0
−$1.4M
2023
$0
−$2.2M
2024
$0
−$2.2M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$0
$0
$0
$0
$0
Cost of goods sold
$563,628
$0
$0
$0
$0
Net income
-$1,062,543
-$1,433,220
-$1,442,937
-$2,183,070
-$2,242,946
Taxes paid
$3,376
$3,442
$1,590
$2,433
-$410
Balance sheet
Cash
$2,793,870
$1,458,412
$722,537
$976,252
$3,045,890
Accounts receivable
$0
$0
$0
$0
$0
Total assets
$2,980,140
$1,570,161
$791,832
$1,290,005
$3,246,152
Short-term debt
$47,364
$85,782
$26,472
$159,014
$160,614
Long-term debt
$4,476
$2,524
$0
$0
$0
Total liabilities
$51,840
$88,306
$26,472
$159,014
$160,614
Other
Headcount
2
2
2
3

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Post-money = pre-money + amount raised · caps marked
$38.9M
post-money
TriAgenics Preferred Stock 1

A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.

Fundraising history

Reg CF Offering (2025)ClosedReg CF · Common Equity · via DEALMAKER SECURITIES LLC
Raised $0 / $3M
TriAgenics Preferred Stock 1ClosedReg CF · Preferred Equity · via StartEngine
Raised $4.9M / $5MInvestors 1,584Post-money $38.9M

Team

9 people
Leigh ColbyFounder
President, CEO, Corporate Secretary, and Director

From 1995 through 2015, Leigh was the founder, CEO, and sole shareholder of Oregon Dental Care, a successful group dental practice in Oregon that delivers high-quality patient care in a zero-defect operating environment. In late 2015, Oregon Dental Care was acquired by InterDent, where he served as the Managing Clinical Director. Prior to starting Oregon Dental Care in 1995, Leigh was involved with three high-tech startups that all remain in successful operation today. In 1980, he was the principal founder of Laserdyne Corporation and wrote the ground-breaking specifications for the successful high-resolution Beam Director general-purpose CNC laser machining system. The Beam Director system remains the #1 selling general-purpose laser machining system worldwide. In 1984, he assisted the PhD EE founder of Cyberoptics Corporation in defining their initial product specifications and market applications to establish initial distribution channels for their unique high- resolution, non-contact laser gauging and automated inspection products. Leigh worked with CyberOptics to develop and implement a marketing plan that drove initial product sales and propelled them to a market leader, where they remain today. In 1986, Leigh teamed up with three PhD-level biochemists as their Vice President of Marketing to define and establish their first commercial operations for Surmodics, Inc. His 10-year effort at Surmodics ultimately resulted in revenues approaching $100M annually for the use of PhotoLink high-reliability biocompatibility enhancement technology on a variety of widely recognized implant and disposable medical devices. Surmodics remains a publicly traded operation. Leigh has earned his M.B.A. degree from Northwest Christian University, D.D.S. and B.S. degrees from the University of Minnesota, and B.S. degree from St. John’s University and is a certified Lean Six Sigma Master Black Belt.

David Thrower
Chief Executive Officer
David Paul Watson
Director & Chief of Operations

Dave brings 25 years of leadership experience to the management team at TriAgenics, Inc. Dave worked for 15 years with IBM in Engineering, Manufacturing, and Product Development, where he held key technical and senior management positions, including critical strategist at IBM Technology Products Division headquarters. He filled the positions of Director of Technology at Planar Systems, Inc., Director of Engineering at Fujitsu Ltd., Director of Manufacturing at Biotronik, Inc., and VP of Engineering at Unilife Medical Solutions, Inc. Dave has patents in the fields of automated equipment and technology products. Dave is the Chief of Operations at TriAgenics, Inc. and is responsible for quality assurance, regulatory affairs, product development, and manufacturing. He holds an MSME from the University of Texas and a BSME from California Polytechnic State University in California.

David Scott Thrower
Board Member

David has more than 30 years of experience with medical device companies,ranging from VP of Marketing for Align Technology (makers of Invisalign) to CEO of several medical device start-ups. He has also served as a Board member of a number of companies, including Aerin Medical, uLab Systems, and Triagenics. David has experience in a wide range of company functions, including sales, marketing, R&D, business development, and manufacturing, for companies with both medical device and consumer applications.

George Shahin
Board Member

George is board-certified in Internal Medicine and Gastroenterology by the American Board of Internal Medicine. He is a member of the American College of Gastroenterology and the American Medical Association.

Jeffrey Miles Jacobs
Board Member

Jeff is the former CEO of Stradis Healthcare, which was acquired in 2021 by Henry Schein, a Fortune 500 Company. He has more than 20 years of experience in the medical device packaging industry.

John Joseph Chopack Jr
Board Member

John is VP Corporate Development for Neoss Ltd., a dental solutions company headquartered in Europe. He leads all external business development activities, including acquisitions and partnerships. Prior to joining Neoss, John was a Principal and founding partner of Inspiros Ventures. John managed the day-to-day operations of Inspiros and was responsible for investment origination, portfolio company management, and investor relations. Johnhas 20 years of experience in private equity/venture capital investing in medtech companies. As a General Partner at HealthpointCapital, a $800 million AUM medtech-focused private equity firm, John played an integral role in the firm’s most profitable investments – Nexa Orthopedics, BioHorizons, and Blue Belt Technologies. These investments brought significant advances to the healthcare field and provided top quartile returns to investors. Prior to his career in venture capital, John was an orthopedic sales representative for Wright Medical and Encore Orthopedics. Following his experience as an orthopedic sales representative, John worked on Wall Street with Investec and Techvest as a medtech analyst. John has been recognized as a “40 under 40 Medtech Innovator” by Medical Device and Diagnostic Industry Magazine. John received a BA from Lafayette College and an MBA from Fordham University Gabelli School of Business.

Dave Watson
Director
David Jahns
Director

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not required3+ reports filed & assets ≤ $10M

Filed 3 of 3 annual reports (FY2023–FY2025)

1,584 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form C-ARApr 29, 20260001872856-26-000134
    EDGAR
  • Form C/AJan 30, 20260001872856-26-000038
    EDGAR
  • Form C/ANov 26, 20250001872856-25-000041
    EDGAR
  • Form CNov 20, 20250001872856-25-000034
    EDGAR
  • Form DApr 17, 20250001732710-25-000002
    EDGAR
  • Form C-ARJan 21, 20250001665160-25-000092
    EDGAR
  • Form C-UDec 12, 20240001665160-24-001797
    EDGAR
  • Form C/AAug 19, 20240001665160-24-001196
    EDGAR
Source: ManualCIK 0001732710DEShare price $4.50

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.